ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
ARQTArcutis Biotherapeutics(ARQT) Newsfilter·2024-01-22 21:00

First drug approved for seborrheic dermatitis with a new mechanism of action in over two decades available in pharmacies this weekEffective, safe, and very well-tolerated steroid-free foam provides rapid disease clearance and significant reduction in itchSeborrheic dermatitis affects more than 10 million people in the United StatesManagement will host conference call on Monday, January 22 at 1:30 pm PST/4:30 pm EST WESTLAKE VILLAGE, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NA ...